Skip to main content

Advertisement

Table 1 Univariate analysis of risk factors associated with treatment delay in TBM patients

From: Total delay in treatment among tuberculous meningitis patients in China: a retrospective cohort study

  Short delay Long delay Total P value
N 84 77 161  
Age (years) 28.3 ± 16.9 34.1 ± 17.2 31.1 ± 17.2 0.037
Sex (male) 48 40 88 0.509
Time during hospitalization (days) 56.6 ± 44.6 64.6 ± 47.1 60.4 ± 45.9 0.273
Fees ($) 78,721 ± 71,922 98,186 ± 108,770 88,030 ± 91,645 0.192
Previous anti-TB therapy 5 14 19 0.022
Smoking habit (pack-years) 2.82 ± 9.10 3.36 ± 11.9 3.08 ± 10.50 0.746
Contact history of TB 10 8 18 0.761
No. of Healthcare visits 2.3 ± 0.9 2.8 ± 1.3 2.5 ± 1.1 0.010
Comorbidity
 Pulmonary TB 54 55 109 0.334
 Extrapulmonary TB 23 25 48 0.481
 Rheumatic diseases 3 5 8 0.401
 Diabetes mellinus 3 8 11 0.434
 Milliary TB 22 29 51 0.120
 Recurrent TB 3 9 12 0.064
Symptoms
 Fever 68 48 116 0.010
 Headache 63 27 90 0.000
 Vomitting 23 8 31 0.008
 Cough 10 20 30 0.025
 Hydrocephalus 13 5 18 0.147
 Abnormalty in brain CT 37 27 64 0.941
CSF examination
 WBC (109/L) 207 ± 210 187 ± 183 198 ± 198 0.524
 Mononuclear cells (%) 64 ± 28 54 ± 28 59 ± 29 0.041
 Polynuclear cells (%) 36 ± 29 46 ± 28 41 ± 28 0.037
 Glucose (mmol/L) 1.96 ± 1.21 2.26 ± 1.81 2.11 ± 1.53 0.223
 Tryptophan (+) 59 49 108 0.708
 Lactate (mmol/L) 6.75 ± 2.37 6.40 ± 2.43 6.58 ± 2.39 0.410
 AST (U/L) 18.7 ± 16.5 17.8 ± 10.5 18.3 ± 13.9 0.671
 LDH (U/L) 136 ± 209 120 ± 138 129 ± 178 0.569
 CSF-PR (mg/L) 1323 ± 649 1456 ± 758 1387 ± 704 0.230
 α-HBDH (U/L) 131 ± 402 70 ± 73 102 ± 296 0.257
 Chloride (mmol/L) 108 ± 8 111 ± 8 109 ± 8 0.038
 ADA (U/L) 8.1 ± 8.1 8.5 ± 6.4 8.3 ± 7.3 0.738
 CSF/Serum glucose 0.32 ± 0.18 0.32 ± 0.18 0.32 ± 0.18 0.932
Serum glucose (mmol/L) 6.30 ± 1.54 7.07 ± 3.27 6.66 ± 2.53 0.084